Vaccination against type 1 diabetes

Journal of Internal Medicine

Volumn 269, Issue 6, 2011, Pages 626-635

  Larsson, H E ^a   Lernmark, A ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Autoantibodies; GAD65; IA 2; Insulin; ZnT8 transporter

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CYCLOSPORIN; DIAMYD; GLUTAMATE DECARBOXYLASE 65; IMMUNOSUPPRESSIVE AGENT; INSULIN; MONOCLONAL ANTIBODY CD3; PREDNISOLONE; RITUXIMAB; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; ZINC TRANSPORTER;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL DESTRUCTION; CELL FUNCTION; DENDRITIC CELL; DIABETIC PATIENT; DISEASE COURSE; GENETIC VARIABILITY; HLA SYSTEM; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; PANCREAS ISLET BETA CELL; PHASE 2 CLINICAL TRIAL (TOPIC); PRICK TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; VACCINATION; VIRUS NEUTRALIZATION;

ANIMALS; AUTOANTIBODIES; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ACTIVE; INSULIN-SECRETING CELLS; MICE;

EID: 79956277614     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02386.x     Document Type: Article

References (62)

1. DPT-1. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Eng J Med 2002; 346: 1685-91.
2. Orban T, Sosenko JM, Cuthbertson D et al. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1. Diabetes Care 2009; 32: 2269-74.
3. Pipeleers D, Ling Z. Pancreatic beta cells in insulin-dependent diabetes. Diabetes Metab Rev 1992; 8: 209-27.
4. Wallensteen M, Dahlquist G, Persson B et al. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia 1988; 31: 664-9.
5. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009; 361: 2143-52.
6. Ludvigsson J, Faresjo M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359: 1909-20.
7. Porksen S, Laborie LB, Nielsen L et al. Disease progression and search for monogenic diabetes among children with new onset type 1 diabetes negative for ICA, GAD- and IA-2 Antibodies. BMC Endocr Disord 2010; 10: 16.
8. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab 2009; 94: 4635-44.
9. Leslie RD, Kolb H, Schloot NC et al. Diabetes classification: grey zones, sound and smoke: Action LADA 1. Diabetes Metab Res Rev 2008; 24: 511-9.
10. Jensen RA, Gilliam LK, Torn C et al. Multiple factors affect the loss of measurable C-peptide over 6years in newly diagnosed 15- to 35-year-old diabetic subjects. J Diabetes Complications 2007; 21: 205-13.
11. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol 2011 Feb 22. [Epub ahead of print].
12. Pipeleers D, Chintinne M, Denys B, Martens G, Keymeulen B, Gorus F. Restoring a functional beta-cell mass in diabetes. Diabetes Obes Metab 2008; 10(Suppl 4): 54-62.
13. Lakey JR, Mirbolooki M, Shapiro AM. Current status of clinical islet cell transplantation. Methods Mol Biol 2006; 333: 47-104.
14. Vendrame F, Pileggi A, Laughlin E et al. Recurrence of type 1 diabetes after simultaneous pancreas-kidney transplantation, despite immunosuppression, is associated with autoantibodies and pathogenic autoreactive CD4 T-cells. Diabetes 2010; 59: 947-57.
15. Uibo R, Lernmark A. GAD65 autoimmunity-clinical studies. Adv Immunol 2008; 100: 39-78.
16. Geffner ME, Lippe BM. The role of immunotherapy in type I diabetes mellitus. West J Med 1987; 146: 337-43.
17. Skyler JS. Immune intervention studies in insulin-dependent diabetes mellitus. Diabetes Metab Rev 1987; 3: 1017-35.
18. Skyler JS. Immunomodulation for type 1 diabetes mellitus. Int J Clin Pract Suppl 2010; 166: 59-63.
19. Bougneres PF, Carel JC, Castano L et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. N Engl J Med 1988; 318: 663-70.
20. Cyclosporin-induced remission of IDDM after early intervention. Association of 1yr of cyclosporin treatment with enhanced insulin secretion. The Canadian-European Randomized Control Trial Group. Diabetes 1988; 37: 1574-82.
21. Martin S, Schernthaner G, Nerup J et al. Follow-up of cyclosporin A treatment in type 1 (insulin-dependent) diabetes mellitus: lack of long-term effects. Diabetologia 1991; 34: 429-34.
22. Kaufman A, Herold KC. Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab Res Rev 2009; 25: 302-6.
23. Jaume JC, Parry SL, Madec AM, Sonderstrup G, Baekkeskov S. Suppressive effect of glutamic acid decarboxylase 65-specific autoimmune B lymphocytes on processing of T cell determinants located within the antibody epitope. J Immunol 2002; 169: 665-72.
24. Steed J, Gilliam LK, Harris RA, Lernmark A, Hampe CS. Antigen presentation of detergent-free glutamate decarboxylase (GAD65) is affected by human serum albumin as carrier protein. J Immunol Methods 2008; 334: 114-21.
25. Buonaguro FM, Tornesello ML, Buonaguro L. Virus-like particle vaccines and adjuvants: the HPV paradigm. Expert Rev Vaccines 2009; 8: 1379-98.
26. La Torre D, Lernmark A. Immunology of beta-cell destruction. Adv Exp Med Biol 2010; 654: 537-83.
27. Wenzlau JM, Frisch LM, Gardner TJ, Sarkar S, Hutton JC, Davidson HW. Novel antigens in type 1 diabetes: the importance of ZnT8. Curr Diab Rep 2009; 9: 105-12.
28. Hampe CS, Kockum I, Landin-Olsson M et al. GAD65 antibody epitope patterns of type 1.5 diabetic patients are consistent with slow-onset autoimmune diabetes. Diabetes Care 2002; 25: 1481-2.
29. Bekris LM, Jensen RA, Lagerquist E et al. GAD65 autoantibody epitopes in adult patients with latent autoimmune diabetes following GAD65 vaccination. Diabet Med 2007; 24: 521-6.
30. Patterson CC, Dahlquist GG, Gyurus E, Green A, Soltesz G. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373: 2027-33.
31. Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009; 360: 1646-54.
32. Roivainen M, Klingel K. Virus infections and type 1 diabetes risk. Curr Diab Rep 2010; 10: 350-6.
33. Schlosser M, Mueller PW, Torn C, Bonifacio E, Bingley PJ. Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies. Diabetologia 2010; 53: 2611-20.
34. Bonifacio E, Yu L, Williams AK et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab 2010; 95: 3360-7.
35. Bonifacio E, Mayr A, Knopff A, Ziegler AG. Endocrine autoimmunity in families with type 1 diabetes: frequent appearance of thyroid autoimmunity during late childhood and adolescence. Diabetologia 2009; 52: 185-92.
36. Stene LC, Oikarinen S, Hyoty H et al. Enterovirus infection and progression from islet autoimmunity to type 1 diabetes: the Diabetes and Autoimmunity Study in the Young (DAISY). Diabetes 2011; 59: 3174-80.
37. Nanto-Salonen K, Kupila A, Simell S et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008; 372: 1746-55.
38. Larsson HE, Hansson G, Carlsson A et al. Children developing type 1 diabetes before 6years of age have increased linear growth independent of HLA genotypes. Diabetologia 2008; 51: 1623-30.
39. The Environmental Determinants of Diabetes in the Young (TEDDY) study: study design. Pediatr Diabetes 2007; 8: 286-98.
40. In't Veld P, Lievens D, De Grijse J et al. Screening for insulitis in adult autoantibody-positive organ donors. Diabetes 2007; 56: 2400-4.
41. Mackay IR, Rowley MJ. Autoimmune epitopes: autoepitopes. Autoimmun Rev 2004; 3: 487-92.
42. Mallone R, van Endert P. T cells in the pathogenesis of type 1 diabetes. Curr Diab Rep 2008; 8: 101-6.
43. Csorba TR, Lyon AW, Hollenberg MD. Autoimmunity and the pathogenesis of type 1 diabetes. Crit Rev Clin Lab Sci 2010; 47: 51-71.
44. Karlsen AE, Hagopian WA, Grubin CE et al. Cloning and primary structure of a human islet isoform of glutamic acid decarboxylase from chromosome 10. Proc Natl Acad Sci U S A 1991; 88: 8337-41.
45. Tisch R, Yang XD, Singer SM, Liblau RS, Fugger L, McDevitt HO. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature 1993; 366: 72-5.
46. Kaufman DL, Clare-Salzler M, Tian J et al. Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 1993; 366: 69-72.
47. Tian J, Clare-Salzler M, Herschenfeld A et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996; 2: 1348-53.
48. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998; 47: 894-9.
49. Plesner A, Worsaae A, Dyrberg T, Gotfredsen C, Michelsen BK, Petersen JS. Immunization of diabetes-prone or non-diabetes-prone mice with GAD65 does not induce diabetes or islet cell pathology. J Autoimmun 1998; 11: 335-41.
50. Lernmark A, Agardh CD. Immunomodulation with human recombinant autoantigens. Trends Immunol 2005; 26: 608-12.
51. Agardh CD, Cilio CM, Lethagen A et al. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J Diabetes Complications 2005; 19: 238-46.
52. Agardh CD, Lynch KF, Palmer M, Link K, Lernmark A. GAD65 vaccination: 5years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009; 52: 1363-8.
53. Oak S, Gilliam LK, Landin-Olsson M et al. The lack of anti-idiotypic antibodies, not the presence of the corresponding autoantibodies to glutamate decarboxylase, defines type 1 diabetes. Proc Natl Acad Sci U S A 2008; 105: 5471-6.
54. Ortqvist E, Brooks-Worrell B, Lynch K et al. Changes in GAD65Ab-specific antiidiotypic antibody levels correlate with changes in C-peptide levels and progression to islet cell autoimmunity. J Clin Endocrinol Metab 2010; 95: E310-8.
55. Ludvigsson J. The role of immunomodulation therapy in autoimmune diabetes. J Diabetes Sci Technol 2009; 3: 320-30.
56. Ludvigsson J, Hjorth M, Cheramy M et al. Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial. Diabetologia 2011; 54: 634-40.
57. Cheramy M, Skoglund C, Johansson I, Ludvigsson J, Hampe CS, Casas R. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response. Clin Immunol 2010; 137: 31-40.
58. Hjorth M, Axelsson S, Ryden A, Faresjo M, Ludvigsson J, Casas R. GAD-alum treatment induces GAD65-specific CD4+ CD25highFOXP3+ cells in type 1 diabetic patients. Clin Immunol 2010; 138: 117-26.
59. Fourlanos S, Perry C, Gellert SA et al. Evidence That Nasal Insulin Induces Immune Tolerance to Insulin in Adults With Autoimmune Diabetes. Diabetes 2011; 60: 1237-45.
60. Skyler JS, Krischer JP, Wolfsdorf J et al. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial - Type 1. Diabetes Care 2005; 28: 1068-76.
61. Schloot NC, Meierhoff G, Lengyel C et al. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab Res Rev 2007; 23: 276-85.
62. Boettler T, Herrath MV. Type 1 diabetes vaccine development: animal models vs. humans. Hum Vaccin 2011; 7. [Epub ahead of print].